Literature DB >> 33755907

Generation of Murine Induced Pluripotent Stem Cells through Transposon-Mediated Reprogramming.

Thirumala R Talluri1, Dharmendra Kumar2, Wilfried A Kues3.   

Abstract

The seminal discovery of induced pluripotent stem (iPS) cells through ectopic expression of a cocktail of gene factors (OCT4, SOX2, KLF4, and c-MYC) by the group of Yamanaka was a major breakthrough, gained widespread acclaim and garnered much attention in the field of stem cell science. The iPS cells possess most of the characteristics and advantages of embryonic stem (ES) cells without the association of ethical stigma for their derivation. In addition, these cells can give rise to any cell type of the body and thus have tremendous potential for many downstream applications in research and regenerative medicine. The original method requires viral transduction of several reprogramming factors, which may be associated with an increased risk of oncogenicity and insertional mutagenesis. Nonviral methods for generation of iPS cells through somatic cell reprogramming are powerful tools for establishing in vitro disease models, development of new protocols for treatment of different diseases, and creating transgenic mice models. Here, we present a detailed protocol for the generation of transposon-mediated iPS cells from mouse embryonic fibroblasts (MEFs) and give a short overview of the characterization of the generated iPS cell lines.
© 2021. Springer Science+Business Media, LLC.

Entities:  

Keywords:  DNA transposon; Embryonic fibroblasts; Induced pluripotent stem cells; Mouse; Oct4-GFP reporter; Pluripotency; Reprogramming; Sleeping Beauty; piggyBac

Mesh:

Substances:

Year:  2022        PMID: 33755907     DOI: 10.1007/7651_2021_350

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  4 in total

Review 1.  Transposon-based reprogramming to induced pluripotency.

Authors:  Dharmendra Kumar; Thirumala R Talluri; Taruna Anand; Wilfried A Kues
Journal:  Histol Histopathol       Date:  2015-08-24       Impact factor: 2.303

2.  The expanding universe of transposon technologies for gene and cell engineering.

Authors:  Zoltán Ivics; Zsuzsanna Izsvák
Journal:  Mob DNA       Date:  2010-12-07

Review 3.  Preclinical and clinical advances in transposon-based gene therapy.

Authors:  Jaitip Tipanee; Yoke Chin Chai; Thierry VandenDriessche; Marinee K Chuah
Journal:  Biosci Rep       Date:  2017-12-05       Impact factor: 3.840

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.